Biozipcode, Inc. (hereinafter referred to as “Biozipcode”) is pleased to announce its business collaboration with Co-LABO MAKER, a venture company originating from Tohoku University and operator of the research resource sharing platform “Co-LABO MAKER” (https://co-labo-maker.com/).

The details of the collaboration with Co-LABO MAKER are as follows:

Professor Hideto Kojima (Special Professor at Shiga University of Medical Science and Head of Research and Development at Biozipcode) has discovered abnormal stem cells that contribute to the incurability of diabetes. Biozipcode is developing new diagnostic drugs targeting these abnormal stem cells and groundbreaking pharmaceuticals that could completely cure diabetes. This development, enabled by the repositioning of existing drugs, significantly shortens the development period. Biozipcode aims to produce these treatments not only as intravenous injections but also as oral medications. Through Co-LABO MAKER’s platform, Biozipcode is looking forward to building cooperative relationships with various players and more robustly advancing this socially significant project.

As previously reported on September 12, 2022, Biozipcode has been utilizing its accumulated technology and expertise from research activities for business purposes, focusing on advisory services related to diabetes and regenerative medicine. With this collaboration with Co-LABO MAKER, we will publicize specific research resources such as regenerative medicine and animal experiments (mice, rats, zebrafish) on “Co-LABO MAKER,” facilitating matches with pharmaceutical and health food manufacturers, research institutions, and other potential advisory service clients.

Overview of Co-LABO MAKER is as follows:

Biozipcode, Inc. (hereinafter referred to as “Biozipcode”), a subsidiary of our company, is excited to announce its business collaboration with Co-LABO MAKER, a venture company originating from Tohoku University and operator of the research resource sharing platform “Co-LABO MAKER” (https://co-labo-maker.com/).

The details of the collaboration with Co-LABO MAKER are as follows:

Professor Hideto Kojima (Special Professor at Shiga University of Medical Science and Head of Research and Development at Biozipcode) has discovered abnormal stem cells that contribute to the incurability of diabetes. Biozipcode is developing new diagnostic drugs targeting these abnormal stem cells and groundbreaking pharmaceuticals that could completely cure diabetes. This development, enabled by the repositioning of existing drugs, significantly shortens the development period. Biozipcode aims to produce these treatments not only as intravenous injections but also as oral medications. Through Co-LABO MAKER’s platform, Biozipcode is looking forward to building cooperative relationships with various players and more robustly advancing this socially significant project.

As previously reported on September 12, 2022, Biozipcode has been utilizing its accumulated technology and expertise from research activities for business purposes, focusing on advisory services related to diabetes and regenerative medicine. With this collaboration with Co-LABO MAKER, we will publicize specific research resources such as regenerative medicine and animal experiments (mice, rats, zebrafish) on “Co-LABO MAKER,” facilitating matches with pharmaceutical and health food manufacturers, research institutions, and other potential advisory service clients.